IP Library › Granted Patent US 12,343,350
Granted Patent B2
US 12,343,350 · App. 18/150,870 · Granted Jul 1, 2025

Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

Inventors: Giuseppe Bianchi (Milan, IT); Patrizia Ferrari (Varese, IT); Mara Ferrandi (Milan, IT); Paolo Barassi (Castelveccana, IT)
Assignee: Windtree Therapeutics, Inc.
A61K31/5685A61K9/009A61P9/04A61P9/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,343,350
App. No.
18/150,870
Granted
Jul 1, 2025
Kind
B2
Abstract

Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.

Claims (35)

1. A compound having a formula (III)

or a pharmaceutically acceptable salt, ester, solvate, hydrate, or polymorph thereof.

2. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, or polymorph thereof in an admixture with at least one pharmaceutically acceptable vehicle and/or excipient.

3. The pharmaceutical composition of claim 2 , further comprising at least one additional therapeutic ingredient.

4. The pharmaceutical composition of claim 3 , wherein the at least one additional therapeutic ingredient is selected from the group consisting of an ACE inhibitor, an AIRB, a diuretic, a Ca channel blocker, a beta-blocker, digitalis , an NO donor, a vasodilator, a SERCA2a stimulator, a neprilisin (NEP) inhibitor, a myosin filament activator, a recombinant relaxin-2 mediator, a recombinant NP protein, an activator of the soluble Guanylate Cyclase (sGC), and a beta-arrestin ligand of Angiotensin II receptor.

5. The pharmaceutical composition of claim 3 , wherein the at least one additional therapeutic ingredient is selected from the group consisting of furosemide, bumetanide, torasemide, metolazone, spironolactone, eplerenone, hydrochlorothiazide, metolazone, chlorthalidone, lisinopril, ramipril, valsartan, candesartan, olmesartan, telmisartan, losartan, sacubitril, carvedilol, metoprolol, hydralazine, hydralazine combined with isosorbide dinitrate, nitroglycerin, isosorbide nitrate, amlodipine, felodipine, diltiazem, verapamil, Digoxin, entresto, omecantiv, serelaxin, ularitide, and levosimendan.

6. The pharmaceutical composition of claim 3 , wherein the at least one additional therapeutic ingredient is in the same or in a separate unit dosage form of the compound having formula (III), or a pharmaceutically acceptable salt, solvate, hydrate, or polymorph thereof.

7. A method for treating an individual having heart failure, the method comprising the steps of:

(1) providing an individual having heart failure;

(2) administering to the individual a therapeutically effective amount of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier; and (ii) istaroxime or a pharmaceutically acceptable salt, solvate, or hydrate thereof: wherein said administering comprises intravenous infusion for an infusion duration sufficient to produce in the individual a plasma concentration level of an istaroxime metabolite, wherein:

(i) the plasma concentration level is greater than about 5 ng/ml for an accumulation period longer than 6 hours; and

(ii) the istaroxime metabolite comprises the compound of claim 1 ; and

(3) measuring one or more parameters of heart function, wherein the one or more parameters of heart function comprises diastolic relaxation;

wherein the administering of the pharmaceutical composition results in an improvement in diastolic relaxation as compared to istaroxime administered by intravenous infusion prior to the accumulation period, thereby treating the individual having acute heart failure.

8. The method of claim 7 , wherein the individual is human.

9. The method of claim 7 , wherein the infusion duration is sufficient to produce in the individual a plasma concentration level of an istaroxime metabolite greater than about 10 ng/ml for an accumulation period longer than 6 hours.

10. The method of claim 7 , wherein the infusion duration is sufficient to produce in the individual a plasma concentration level of an istaroxime metabolite greater than about 15 ng/ml for an accumulation period longer than 6 hours.

11. The method of claim 7 , wherein the infusion duration is sufficient to produce in the individual a plasma concentration level of an istaroxime metabolite greater than about 20 ng/ml for an accumulation period longer than 6 hours.

12. A method for treating an individual having heart failure, the method comprising the steps of:

(1) providing an individual having heart failure;

(2) administering to the individual a therapeutically effective amount of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier; and (ii) the compound of claim 1 , wherein said administering comprises intravenous infusion;

(3) measuring one or more parameters of heart function, wherein the one or more parameters of heart function comprises diastolic relaxation;

wherein the administering of the pharmaceutical composition results in an improvement in diastolic relaxation, thereby treating the individual having acute heart failure.

13. The method of claim 12 , wherein the compound is administered at a dose of about 0.2 mcg/kg/min to about 1.5 mcg/kg/min.

14. The method of claim 12 , wherein the administering comprises intravenous infusion for an infusion duration selected from:

at least about 6 hours;

at least about 12 hours;

at least about 24 hours;

at least about 36 hours; and

at least about 48 hours.

15. The method of claim 12 , wherein the improvement in diastolic heart function is measured by echocardiography, a sphygmomanometer, an electrocardiogram, cardiac catheterization, a radionuclide ventriculography scan, or any combination thereof.

16. The method of claim 12 , wherein the improvement in diastolic heart function comprises one or more of improved diastolic relaxation, increased diastolic blood pressure, decreased heart rate, a decrease in dyspnea, increased stroke volume, increased cardiac index, increased cardiac output, increased pulmonary capillary wedge pressure, or increased stroke volume index.

17. The method of claim 12 , wherein the individual is human.

18. The method of claim 12 , wherein the pharmaceutical composition further comprises at least one additional therapeutic ingredient.

19. The method of claim 18 , wherein the at least one additional therapeutic ingredient is selected an ACE inhibitor, an AIRB, a diuretic, a Ca channel blocker, a beta-blocker, digitalis , an NO donor, a vasodilator, a SERCA2a stimulator, a neprilysin (NEP) inhibitor, a myosin filament activator, a recombinant relaxin-2 mediator, a recombinant NP protein, an activator of the soluble Guanylate Cyclase (sGC), and a beta-arrestin ligand of Angiotensin II receptor.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2026
From: WINDTREE THERAPEUTICS INC.
To: SEISMIC PHARMACEUTICALS
Reel/Frame 073612/0152 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2026
From: SEISMIC PHARMACEUTICALS INC.
To: SEISMIC PHARMACEUTICALS OPERATIONS LLC
Reel/Frame 073612/0258 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2026
From: SEISMIC PHARMACEUTICALS INC.
To: SEISMIC PHARMACEUTICALS OPERATIONS LLC
Reel/Frame 073612/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2025
From: WINDTREE THERAPEUTICS INC.
To: SEISMIC PHARMACEUTICALS
Reel/Frame 073018/0285 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2023
From: BIANCHI, GIUSEPPE; FERRARI, PATRIZIA; FERRANDI, MARA; BARASSI, PAOLO
To: WINDTREE THERAPEUTICS, INC.
Reel/Frame 062318/0134 →
Continuity (5)
Continuation 17517530 · Nov 2, 2021
Continuation 17233302 · Apr 16, 2021
Continuation PCTUS2019060961 · Nov 12, 2019
Provisional Application 62814149 · Mar 5, 2019
Related Publication 20230293548A1 · Sep 21, 2023
References Cited (123)
US 4534899A · Sears · 1985 [cited by applicant]
US 5846743A · Janmey et al. · 1998 [cited by applicant]
US 5874268A · Meyer · 1999 [cited by applicant]
US 6007839A · Mayhew et al. · 1999 [cited by applicant]
US 6063400A · Geho et al. · 2000 [cited by applicant]
US 6261815B1 · Meyer · 2001 [cited by applicant]
US 6384250B2 · Gobbini · 2002 [cited by applicant]
US 6589503B1 · Piwnica-Worms · 2003 [cited by applicant]
US 7109034B2 · Orwar et al. · 2006 [cited by applicant]
US 7306783B2 · Piwnica-Worms · 2007 [cited by applicant]
US 20040028670A1 · Carlson et al. · 2004 [cited by applicant]
US 20040151766A1 · Monahan et al. · 2004 [cited by applicant]
US 20050136121A1 · Kershman et al. · 2005 [cited by applicant]
US 20060083737A1 · Minomi et al. · 2006 [cited by applicant]
US 20070042031A1 · Maclachlan et al. · 2007 [cited by applicant]
US 20070077286A1 · Ishihara et al. · 2007 [cited by applicant]
US 20070082042A1 · Park et al. · 2007 [cited by applicant]
US 20070110798A1 · Drummond et al. · 2007 [cited by applicant]
US 20100087374A1 · Ahmad et al. · 2010 [cited by applicant]
US 20100087500A1 · Stover · 2010 [cited by applicant]
US 20160151461A1 · Shannon · 2016 [cited by applicant]
CN 103316968B · 2015 [cited by applicant]
EP 0825197B1 · 1998 [cited by applicant]
WO WO2014086870A1 · 2014 [cited by applicant]
Gobbini et al., 18 Bioorg. Med. Chem. 4275-4299 (2010) (Year: 2010). [cited by examiner]
Lanoxin ® Prescribing Information (Revised Feb. 2019) (Year: 2019). [cited by examiner]
Abraham et al., “In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)” … [cited by applicant]
Alemanni et al. “Role and mechanism of subcellular Ca2+ distribution in the action of two inotropic agents with different toxicity” J Mol Cell Cardiol 50:910-8 (2011). [cited by applicant]
Al-Muhammed, “In-vivo studies on dexamethasone sodium phosphate liposomes” J. Microencapsul. 13:293-306 (1996). [cited by applicant]
Asahi et al., “Transmembrane helix M6 in sarco(endo)plasmic reticulum Ca(2+)-ATPase forms a functional interaction site with phospholamban. Evidence for physical interactions at other sites” J Biol Chem 274: 32855-32862… [cited by applicant]
Ashkar & Makaryus, “Dobutamine”, In StatPearls [Internet], Treasure Island (FL): SlatPearls Publishing, Jan. 2017-Jan. 2018 (available at https://www.ncbi.nlm.nih.gov/books/NBK470431/). [cited by applicant]
Baheti et al., “Excipients used in lyophilization of small molecules” J. Excipients and Food Chem. 1(1):41-54 (2010). [cited by applicant]
Bers et al., “Regulation of Ca2+ and Na+ in normal and failing cardiac myocytes” Ann N.Y. Acad Sci 2006; 1080:165-177 (2006). [cited by applicant]
Bers, “Altered cardiac myocyte Ca regulation in heart failure” Physiology 21: 380-387 (2006). [cited by applicant]
Bers, “Calcium cycling and signaling in cardiac myocytes” Annu Rev Physiol 70:23-49 (2008). [cited by applicant]
Braunwald, “The war against heart failure: the Lancet lecture” 2015; 385:812-24 (2015). [cited by applicant]
Brophy et al., “Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients” Eur. J. Clin. Pharmacol. 24:103-108 (1983). [cited by applicant]
Bonsu et al., “Pharmacological treatments for heart failure with preserved ejection fraction—a systematic review and indirect comparison” Heart Failure Reviews 23:147-156 (2018). [cited by applicant]
Butler et al., Past, present, and future of acute heart failure clinical trials—a high-risk population in search of a strategy Eur J Heart Fail.20(5):839-841 (2018). [cited by applicant]
Byrne et al., “Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals” Gene Therapy 15:1550-1557 (2008). [cited by applicant]
Campla et al. “Acute Heart Failure with Low Cardia Output: Can We Develop a Short-term Inotropic Agent that Does Not Increase Adverse Events?” Curr. Heart Fall. Rep. 7:100-109 (2010). [cited by applicant]
Carillion et al., “Atorvastatin reduces β-Adrenergic dysfunction in rats with diabetic cardiomyopathy” PloS One e0180103 (2017). [cited by applicant]
Choi et al., “Defective intracellular Ca2+ signaling contributes to cardiomyopathy in Type 1 diabetic rats” Am. J. Physiol. Heart Cir. Physiol 283:H1398-H1408 92002). [cited by applicant]
Chonn & Cullis, “Recent advances in liposomal drug-delivery systems” Curr, Opin. Biotechnol. 6:698-708 (1995). [cited by applicant]
De Munari et al., “Structure-based design and synthesis of novel potent Na+, K+-ATPase inhibitors derived from a 5alpha, 14alpha-androstane scaffold as positive inotropic compounds” J. Med. Chem. 46(17): 3644-3654 (2003… [cited by applicant]
Do Carmo et al., “Chronic central leptin infusion restores cardiac sympathetic-vagal balance and baroreflex sensitivity in diabetic rats” Am. J. Physiol. Heart Cir. Physiol 295:H1974-1981 (2008). [cited by applicant]
Evangelista et al., “European Association of Echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies” Eur J Echocardiogi 9(4):438-48 (2008). [cited by applicant]
Fernandez-Tenorio & Niggli, “Stabilization of Ca 2+ signaling in cardiac muscle by stimulation of Serca” J Mol Cell Cardiol. 119:87-95 (2018). [cited by applicant]
Ferrandi et al., “Renal Na,K-ATPase in genetic hypertension” Hypertension 28(6):1018-25 (1996). [cited by applicant]
Ferrandi et al., “Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition” Br J Pharmacol 169:1849-61 (2013). [cited by applicant]
Flaherty et al., “Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment” J Am Coll Cardiol. 53(3):254-63 (2009). [cited by applicant]
Fotherby, “Bloavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy” Contraception 54:59-69 (1996). [cited by applicant]
Georghiade et al., “Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent” J Am Coll Cardiol.51:2276-85 (2008). [cited by applicant]
Ghio et al., “Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure” J Am Coll Cardiol 37(1):183-8 (2001). [cited by applicant]
Gong et al., “Levosimendan Treatment for Heart Failure: A Systematic Review and Meta-Analysis” J Cardiothorac Vasc Anesth 29:1415-25 (2015). [cited by applicant]
Gröβl et al., “A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves Ca2+ uptake into the sarcoplasmic reticulum” PLoS One 9:e92188 (2014). [cited by applicant]
Guido et al., “The Effects of Diabetes Induction on the Rat Heart: Differences in Oxidative Stress, Inflammatory Cells, and Fibrosis between Subendocardial and Interstitial Myocardial Areas” Oxid Med Cell Longev.2017: 5… [cited by applicant]
Gulati et al., “Mitral annular descent velocity by tissue Doppler echocardiography as an index of global left ventricular function” Am J Cardiol. 77(11):979-84 (1996). [cited by applicant]
Haddad et al., “Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure” Circulation 117(13):1717-31 (2008). [cited by applicant]
Heineke & Molkentin, “Regulation of cardiac hypertrophy by intracellular signalling pathways” Nat Rev 7:589-600 (2006). [cited by applicant]
Hidalgo-Aragones et al., “Pharmacokinetics of oestrone-3-O-sulphamate” Steroid Biochem. Mol. Biol. 58:611-617 (1996). [cited by applicant]
Hoshijima et al., “Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery” Nat. Med. 8:864-871 (2002). [cited by applicant]
Hougen & Friedman, “Age-related effects of digoxin on myocardial contractility and Na-K pump in sheep” Am J Physiol. 243(4):H517-22 (1982). [cited by applicant]
Hulot et al., “Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial” Eur Heart J 19:1534-… [cited by applicant]
Iwanaga et al., “Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats” J Clin Invest 113, 727-736 (2004). [cited by applicant]
Joffe et al., “Abnormal cardiac function in the streptozotocin-induced non-insulin-dependent diabetic rat: noninvasive assessment with doppler echocardiography and contribution of the nitric oxide pathway” JACC 34(7):21… [cited by applicant]
Johnson et al., “Permeation of steroids through human skin” J. Pharm. Sci. 84:1144-1146 (1995). [cited by applicant]
Jørgensen, “Purification of Na+,K+-ATPase: enzyme sources, preparative problems, and preparation from mammalian kidney” Methods Enzymol. 156:29-43 (1988). [cited by applicant]
Kaneko et al., “A pyridone derivative activates SERCA2a by attenuating the inhibitory effect of phospholamban” Eur J Pharmacol 814:1-7 (2017). [cited by applicant]
Karim et al., “Phosphorylation-dependent conformational switch in spin-labeled phospholamban bound to SERCA” J Mol Biol 358:1032-1040 (2006). [cited by applicant]
Kaye et al., “Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals” J. Am. Coll. Cardiol. 50:253-260 (2007). [cited by applicant]
Lancellotti et al., “European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease)” Eur J Echocardiogr 11(4):307… [cited by applicant]
Lang et al., “Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Commillee and the Chamber Quantification Writing Group, developed in conjunctio… [cited by applicant]
Lipskaya et al., “Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure” Expert Opin Biol Ther 10:29-41 (2010). [cited by applicant]
Lloyd-Jones et al., “Lifetime risk for developing congestive heart failure: the Framingham Heart Study” Circulation 106:3068-3072 (2002). [cited by applicant]
Lohse et al., “What is the role of beta-adrenergic signaling in heart failure?” Circ Res 93:896-906 (2003). [cited by applicant]
Luciani et al., “Development and physico-chemical characterization of a liposomal formulation of istaroxime” Eur J Pharm Biopharm. 79(2):285-93 (2011). [cited by applicant]
MacLennan & Kranias, “Phospholamban: a crucial regulator of cardiac contractility” Nat Rev Mol Cell Biol 4(7):566-577 (2003). [cited by applicant]
Mann & Bristow, “Mechanisms and models in heart failure: the biomechanical model and beyond” Circulation 111:2837-2849 (2005). [cited by applicant]
Mattera et al., “Istaroxime: a new luso-inotropic agent for heart failure” Am J Cardiol 99(2A):33A-40A (2007). [cited by applicant]
Metra & Teerlink, “Heart failure” Lancet 390:1981-1995 (2017). [cited by applicant]
Micheletti et al., “Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744)” J Pharmacol Exp Ther 303:592-600 (2002). [cited by applicant]
Micheletti et al., “Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure” Am J Card 99(2A):24A-32A (2007). [cited by applicant]
Mihm et al., “Diabetes related cardiomyopathy time dependent echocardiographic evaluation in an experimental rat model” Life Sci. 69(5):527-42 (2001). [cited by applicant]
Minamisawa et al., “Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy” Cell 99:313-322 (1999). [cited by applicant]
Mitter et al., “A Test in Context: E/A and E/e' to Assess Diastolic Dysfunction and LV Filling Pressure” JACC 69(11):1451-1464 (2017). [cited by applicant]
Nagueh et al., “Recommendations for the evaluation of left ventricular diastolic function by echocardiography” Eur J Echocardiogr 10(2):165-93 (2009). [cited by applicant]
Nakayama et al., “Ca2+-and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure” J Clin Invest 117:2431-44 (2007). [cited by applicant]
Nediani et al., “Stimulation of cardiac sarcoplasmic reticulum calcium pump by acylphosphatase. Relationship to phospholamban phosphorylation” J Biol Chem. 271:19066-73 (1996). [cited by applicant]
Nicholson & Turner, “Marine steroids. Part III. On the structure of marthasterone glucoside from the starfish Marthasterals glacialls” J. Chem. Soc. Perkin Trans. 1(12):1357-1360 (1976). [cited by applicant]
No Author listed, “An Account of the Effects of the Digitalis Purpurea in Dropsy” Lond Med J. 6(Pt 1):55-60 (1785). [cited by applicant]
Ostro & Cullis, “Use of liposomes as injectable-drug delivery systems” Am. J. Hosp. Pharm. 46:1576-1587 (1989). [cited by applicant]
Packer, “The Room Where It Happens: A Skeptic's Analysis of the New Heart Failure Guidelines” J. Card. Fail. 22:726-730 (2016). [cited by applicant]
Packer, “Why is the use of digitalis withering? Another reason that we need medical heart failure specialists” Eur J Heart Failure 20:851-852 (2018). [cited by applicant]
Patel et al., “Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF” Circ Heart Failure 7:918-925 (2014). [cited by applicant]
Pellicorí et al., “IVC diameter in patients with chronic heart failure: relationships and prognostic significance” JACC Cardiovasc Imaging 6(1):16-28 (2013). [cited by applicant]
Pinz et al., “Compromised myocardial energetics in hypertrophied mouse hearts diminish the beneficial effect of overexpressing SERCA2a” J Biol Chem 286(12):10163-10168 (2011). [cited by applicant]
Revill et al., “Isaroxime” in Drugs of the Future 32(7):595-600 (2007). [cited by applicant]
Rigopoulus et al., “Acute heart failure. An unmet medical need” Herz44:53-55 (Epub Sep. 22, 2017). [cited by applicant]
Rocchetti et al., “Modulation of sarcoplasmic reticulum function by Na+/K+ pump inhibitors with different toxicity: digoxin and PST2744 [(E,Z)-3-((2-aminoethoxy)imino)androstane-6, 17-dione hydrochloride]” J Pharmacol E… [cited by applicant]
Sabbah et al., “A canine model of chronic heart failure produced by multiple sequential coronary microembolizations” Am J Physiol. 260:H1379-84 (1991). [cited by applicant]
Sabbah et al., “Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure” Am J Cardiol. 99(2A):41A-46A (2007). [cited by applicant]
Sato et al., “Rescue of contractile parameters and myocyle hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation” J Biol Chem 276:9392-99 (2001). [cited by applicant]
Schwinger et al., “Reduced Ca(2+)-sensitivity of SERCA 2a in falling human myocardium due to reduced serin-16 phospholamban phosphorylation” J Mol Cell Cardiol. 31(3):479-91 (1999). [cited by applicant]
Seidler et al., “Cyclopiazonic acid is a specific inhibitor of the Ca2+-ATPase of sarcoplasmic reticulum” J Biol Chem. 264:17816-23 (1989). [cited by applicant]
Shah et al., “Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lu… [cited by applicant]
Shattock et al., “Na+/Ca2+ exchange and Na+/K+-ATPase in the heart” J Physiol. 15;593(6):1361-82 (2015). [cited by applicant]
Solomon et al., “Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure” Circulation 116(13):1482-87 (2007). [cited by applicant]
Tamargo et al. “Investigational Positive Inotropic Agents for Acute Heart Failure” Cardiovasc. & Haematolog. Disorders-Drug Targets 9:193-205 (2009). [cited by applicant]
Teerlink et al., “Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study” J Am Coll Cardiol.67(12):1444-1455 (2016). [cited by applicant]
Teneggi et al., “Drugs' development in acute heart failure: what went wrong?” Heart Failure Rev 23:667-691 (2018). [cited by applicant]
ThackerayJT et al., “Sympathetic nervous dysregulation in the absence of systolic left ventricular dysfunction in a rat model of insulin resistance with hyperglycemia” Cardiovasc Diabetol. 10(75):1-13 (2011). [cited by applicant]
Toyoshima et al., “Modeling of the inhibitory interaction of phospholamban with the Ca2+ ATPase” Proc Natl Acad Sci USA 100:467-47 (2003). [cited by applicant]
Ventura-Clapier et al., “Bioenergetics of the failing heart” Biochim Biophys Acta. 1813(7):1360-72 (2011). [cited by applicant]
Voelkel et al., “Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure” Circulation 114(17):1883-91 (2006… [cited by applicant]
Whitbeck et al., “Increased mortality among patients taking digoxin—analysis from the AFFIRM study” Eur Heart J. 34(20):1481-8 (2013). [cited by applicant]
Zaza & Rocchetti, “Calcium store stability as an antiarrhythmic endpoint” Curr Pharm Des 21:1053-1061 (2015). [cited by applicant]
International Search Report and Written Opinion in International PCT Application No. PCT/US2019/060961, mailed Apr. 6, 2020. [cited by applicant]
Blair et al., “Rationale and Design of the Hemodynamic, Echocardiographic and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: A Randomized Controlled Trial in Patients Hospitaliz… [cited by applicant]
Database Registry, Compound Registration No. 744195-06-0 (Sep. 14, 2004). [cited by applicant]
Arici et al., “Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function” The Journal of Pharmacology and Experimental Therapeutics 384:231-244 (2022). [cited by applicant]
ClinicalTrails.govarchive NCT02617446 (2017) available at https://classic.clinicaltrials.gov/ct2/history/NCT02617446?B=2&A=1&C=merged#StudyPageTop>. [cited by applicant]
EudraCT No. 2008-003531-21 “A multicenter, randomized, double-blind, placebo-controlled parallel-group phase IIb study of the safety and efficacy of istaroxime over 24 hours at three doses in acute decompensated heart f… [cited by applicant]